Cenova Capital

Cenova Capital is a Shanghai-based healthcare-focused venture firm investing across biotech, pharma and therapeutics, and medical devices. The firm’s identity centers on backing Chinese healthcare innovation across multiple stages of company maturity, with a willingness to engage on the scientific and clinical complexities that define meaningful drug, biologic, and device development. Cenova Capital’s stage breadth from Series A through growth signals an intent to support companies as they scale rather than only at a single inflection point. Limited public information is available in English-language sources about individual named partners or a comprehensive portfolio listing in this profile, so direct engagement is the practical path to confirming sector depth.

Check sizes typically run from five to twenty-five million dollars, deployed across Series A, Series B, Series C, and growth-stage rounds. Geographic focus is centered on China, with the firm playing a meaningful role in the kind of healthcare growth rounds that have defined Chinese biotech and medical device fundraising over the past decade. Capital is sized to support clinical milestones, regulatory pathways, and commercial scale-up rather than initial discovery work.

For founders, Cenova Capital is most relevant for healthcare companies operating in China or with serious China expansion plans, particularly those past initial proof and into clinical development or commercialization. Expect a partner that reads science and clinical strategy carefully, engages on regulatory pathways through China’s NMPA, and brings local network advantages around manufacturing and commercialization. Founders without a meaningful China connection will likely find a weaker fit, while teams whose programs benefit from Chinese clinical, manufacturing, or commercial assets will find a substantive sector specialist.